Amendment to the Claims:

Cancel Claims 22, 25, 26, 27, 29, and 30.

Listing of Claims:

1. (original) A compound of structural formula I:



(I)

wherein

each n is independently 0, 1, or 2;

m is 1 or 2;

p is 1 or 2; with the proviso that m + p is 3;

X is N or CR^2;

Ar is phenyl substituted with one to five R^3 substituents;

R^1 and R^2 are each independently selected from the group consisting of

hydrogen,

halogen,

hydroxy,

cyano,

C_{1-10} alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,

C_{1-10} alkoxy, wherein alkoxy is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,

C_{1-10} alkylthio, wherein alkylthio is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,

C_{2-10} alkenyl, wherein alkenyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,

$(CH_2)_nCOOH$,

$(CH_2)_nCOOC_{1-6}$ alkyl,

$(CH_2)_nCONR^4R^5$, wherein R^4 and R^5 are independently selected from the group consisting of hydrogen, tetrazolyl, thiazolyl, $(CH_2)_n$-phenyl, $(CH_2)_n$-C_{3-6} cycloalkyl, and C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;
or R^4 and R^5 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

$(CH_2)_n$-NR^4R^5,

$(CH_2)_n$-$OCONR^4R^5$,

$(CH_2)_n$-$SO_2NR^4R^5$,

$(CH_2)_n$-SO_2R^6,

$(CH_2)_n$-$NR^7SO_2R^6$,

$(CH_2)_n$-$NR^7CONR^4R^5$,

$(CH_2)_n$-NR^7COR^7,

$(CH_2)_n$-$NR^7CO_2R^6$,

$(CH_2)_n$-COR^6,

$(CH_2)_n$-C_{3-6} cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(CH_2)_n$-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, cyano, hydroxy, $NR^7SO_2R^6$, SO_2R^6, CO_2H, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl, and
C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(CH_2)_n$-heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and

$(CH_2)_n$-heterocyclyl, wherein heterocyclyl is unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C_{1-6} alkyl, and C_{1-6}

alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

wherein any methylene (CH_2) carbon atom in R^1 or R^2 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C_{1-4} alkyl unsubstituted or substituted with one to five halogens;

each R^3 is independently selected from the group consisting of

hydrogen,

halogen,

cyano,

hydroxy,

C_{1-6} alkyl, unsubstituted or substituted with one to five halogens, and

C_{1-6} alkoxy, unsubstituted or substituted with one to five halogens;

R^6 is independently selected from the group consisting of tetrazolyl, thiazolyl, $(CH_2)_n$-phenyl, $(CH_2)_n$-C_{3-6} cycloalkyl, and C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and wherein any methylene (CH_2) carbon atom in R^6 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, C_{1-4} alkyl, and C_{1-4} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

each R^7 is hydrogen or R^6;

each R^8, R^9, and R^{10} is independently selected from the group consisting of

hydrogen,

cyano,

carboxy,

C_{1-6} alkyloxycarbonyl,

C_{1-10} alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkoxy, carboxy,

C_{1-6} alkyloxycarbonyl, and phenyl-C_{1-3} alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,

$(CH_2)_n$-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(CH_2)_n$-heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(CH_2)_n$-heterocyclyl, wherein heterocyclyl is unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(CH_2)_n$-C_{3-6} cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and

$(CH_2)_nCONR^4R^5$, wherein R^4 and R^5 are independently selected from the group consisting of hydrogen, tetrazolyl, thiazolyl, $(CH_2)_n$-phenyl, $(CH_2)_n$-C_{3-6} cycloalkyl, and C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;
or R^4 and R^5 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

wherein any methylene (CH_2) carbon atom in R^8, R^9 or R^{10} is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C_{1-4} alkyl unsubstituted or substituted with one to five halogens.

2. (original) The compound of Claim 1 of structural formula Ia wherein the carbon atom marked with an * has the *R* configuration:



(Ia)

3. (original) The compound of Claim 1 of structural formula Ib:



(Ib)

4. (original) The compound of Claim 3 of structural formula Ic wherein the carbon atom marked with an * has the *R* configuration



(Ic)

5. (original) The compound of Claim 3 of structural formula Id:



(Id)

6. (original) The compound of Claim 3 of structural formula Ie:



(Ie)

7. (original) The compound of Claim 1 of structural formula If:



(If)

8. (original) The compound of Claim 7 of structural formula Ig wherein the carbon atom marked with an * has the *R* configuration:



(Ig)

9. (original) The compound of Claim 7 of structural formula Ih:



(Ih)

10. (original) The compound of Claim 7 of structural formula Ii:



(Ii)

11. (original) The compound of Claim 1 wherein R^3 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, trifluoromethyl, and methyl.

12. (original) The compound of Claim 11 wherein R^3 is selected from the group consisting of hydrogen, fluoro, and chloro

13. (original) The compound of Claim 1 wherein R^1 is selected from the group consisting of:

hydrogen,

halogen,

C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,

$(CH_2)_n$-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, CN, hydroxy, $NR^7SO_2R^6$, SO_2R^6, CO_2H, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl, and

C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

$(CH_2)_n$-heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and

wherein any methylene (CH_2) carbon atom in R^1 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C_{1-4} alkyl unsubstituted or substituted with one to five halogens.

14. (original) The compound of Claim 13 wherein R^1 is selected from the group consisting of

hydrogen,

methyl,

trifluoromethyl,
phenyl,
4-fluorophenyl,
4-(trifluoromethyl)phenyl,
4-(trifluoromethoxy)phenyl, and
5-methyl-1,3,4-oxadiazol-2-yl.

15. (original) The compound of Claim 1 wherein R^2 is selected from the group consisting of
hydrogen,
halogen, and
C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy.

16. (original) The compound of Claim 15 wherein R^2 is selected from the group consisting of hydrogen and trifluoromethyl.

17. (original) The compound of Claim 1 wherein R^8, R^9, and R^{10} are independently selected from the group consisting of:
hydrogen and
C_{1-6} alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkoxy, and phenyl-C_{1-3} alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens.

18. (original) The compound of Claim 17 wherein R^8, R^9, and R^{10} are each independently selected from the group consisting of hydrogen and methyl.

19. (original) The compound of Claim 18 wherein R^9 and R^{10} are hydrogen.

20. (original) The compound of Claim 2 which is selected from the group consisting of:

















and



or a pharmaceutically acceptable salt thereof.

21. (original) A pharmaceutical composition which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.

22. (cancelled)

23. (original) A method for treating non-insulin dependent (Type 2) diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

24. (original) A method for treating hyperglycemia in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

25-27. (cancelled)

28. (original) The pharmaceutical composition of Claim 21 further comprising one or more additional active ingredients selected from the group consisting of:

(a) a second dipeptidyl peptidase IV inhibitor;

(b) an insulin sensitizer selected from the group consisting of a PPARγ agonist, a PPARα/γ dual agonist, a PPARα agonist, a biguanide, and a protein tyrosine phosphatase-1B inhibitor;

(c) an insulin or insulin mimetic;

(d) a sulfonylurea or other insulin secretagogue;

(e) an α-glucosidase inhibitor;

(f) a glucagon receptor antagonist;

(g) GLP-1, a GLP-1 mimetic, or a GLP-1 receptor agonist;

(h) GIP, a GIP mimetic, or a GIP receptor agonist;

(i) PACAP, a PACAP mimetic, or a PACAP receptor agonist;

(j) a cholesterol lowering agent such as (i) HMG-CoA reductase inhibitor, (ii) sequestrant, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonist, (v) PPARα/γ dual agonist, (vi) inhibitor of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitor, and (viii) anti-oxidant;

(k) a PPARδ agonist;

(l) an antiobesity compound;

(m) an ileal bile acid transporter inhibitor;

(n) an anti-inflammatory agent; and

(o) an antihypertensive agent.

29-30 (cancelled)